Mid- and Long-term Anxiety Levels Associated with Presymptomatic Testing of Huntington's Disease, Machado-Joseph Disease, and Familial Amyloid Polyneuropathy

Overview

Journal Braz J Psychiatry

Specialty Psychiatry

Date 2016 Feb 13

PMID 26870910

Citations 4

Authors

Susana Ledo

Angela Leite

Teresa Souto

Maria A Dinis

Jorge Sequeiros

Affiliations

Soon will be listed here.

Abstract

Objective: To study anxiety as a variable of the mid- and long-term psychological impact of pre-symptomatic testing for three autosomal dominant late-onset disorders - Huntington's disease (HD), Machado-Joseph disease (MJD) and familial amyloid polyneuropathy (FAP) TTR V30M - in a Portuguese sample.

Methods: This cross-sectional study included 203 participants: 170 (83.7%) underwent pre-symptomatic testing for FAP, 29 (14.3%) for HD, and 4 (2%) for MJD. Of the 203 participants, 73 (36.0%) were asymptomatic carriers, 29 (14.5%) were symptomatic carriers, 9 (4.5%) were diagnosed with FAP and had a liver transplant, and 89 (44.5%) were non-carriers. Most were women (58.1%) and married (66.5%). The anxiety variable was assessed using the Zung Self-Rating Anxiety Scale (SAS).

Results: The anxiety scores were higher for symptomatic carriers and for those who underwent psychological support consultations over the years. For symptomatic carriers, the mean scores were superior to 40 points, which reflects clinical anxiety.

Conclusion: Although it was not possible to differentiate between the mid- and long-term psychological impacts, this study supports the conclusion that the proximity to the age of symptoms onset might be a trigger for anxiety.

Citing Articles

Influence of humanistic care based on Carolina care model for ovarian cancer patients on postoperative recovery and quality of life.

Gao M, Zhang L, Wang Y, Li L, Wang C, Shen Q Am J Transl Res. 2021; 13(4):3390-3399.

PMID: 34017514 PMC: 8129217.

Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis.

Vilas-Boas M, Rocha A, Cardoso M, Fernandes J, Coelho T, Silva Cunha J Front Neurol. 2020; 11:605282.

PMID: 33329366 PMC: 7719818. DOI: 10.3389/fneur.2020.605282.

Psychopathological Dimensions in Portuguese Subjects with Transthyretin Familial Amyloid Polyneuropathy.

Lopes A, Fonseca I, Sousa A, Branco M, Rodrigues C, Coelho T Biomed Hub. 2020; 2(3):1-14.

PMID: 31988916 PMC: 6945894. DOI: 10.1159/000485118.

Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.

Lopes A, Sousa A, Fonseca I, Branco M, Rodrigues C, Coelho T J Community Genet. 2017; 9(1):93-99.

PMID: 29052096 PMC: 5752657. DOI: 10.1007/s12687-017-0338-0.

References

MacLeod R, Tibben A, Frontali M, Evers-Kiebooms G, Jones A, Martinez-Descales A . Recommendations for the predictive genetic test in Huntington's disease. Clin Genet. 2012; 83(3):221-31. DOI: 10.1111/j.1399-0004.2012.01900.x. View

Timman R, Roos R, Maat-Kievit A, Tibben A . Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol. 2004; 23(2):189-97. DOI: 10.1037/0278-6133.23.2.189. View

Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y . The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet. 1993; 4(3):300-4. DOI: 10.1038/ng0793-300. View

Broadstock M, Michie S, Marteau T . Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet. 2000; 8(10):731-8. DOI: 10.1038/sj.ejhg.5200532. View

Decruyenaere M, Evers-Kiebooms G, Cloostermans T, Boogaerts A, Demyttenaere K, Dom R . Predictive testing for Huntington's disease: relationship with partners after testing. Clin Genet. 2004; 65(1):24-31. DOI: 10.1111/j..2004.00168.x. View

Skirton H, Goldsmith L, Jackson L, Tibben A . Quality in genetic counselling for presymptomatic testing--clinical guidelines for practice across the range of genetic conditions. Eur J Hum Genet. 2012; 21(3):256-60. PMC: 3573206. DOI: 10.1038/ejhg.2012.174. View

Licklederer C, Wolff G, Barth J . Mental health and quality of life after genetic testing for Huntington disease: a long-term effect study in Germany. Am J Med Genet A. 2008; 146A(16):2078-85. DOI: 10.1002/ajmg.a.32423. View

Codori A, Brandt J . Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet. 1994; 54(3):174-84. DOI: 10.1002/ajmg.1320540304. View

. International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet. 1994; 31(7):555-9. PMC: 1049979. DOI: 10.1136/jmg.31.7.555. View

10.

Paneque H, Prieto A, Reynaldo R, Cruz M, Santos F, Almaguer M . Psychological aspects of presymptomatic diagnosis of spinocerebellar ataxia type 2 in Cuba. Community Genet. 2007; 10(3):132-9. DOI: 10.1159/000101754. View

11.

Paneque M, Lemos C, Sousa A, Velazquez L, Fleming M, Sequeiros J . Role of the disease in the psychological impact of pre-symptomatic testing for SCA2 and FAP ATTRV30M: Experience with the disease, kinship and gender of the transmitting parent. J Genet Couns. 2009; 18(5):483-93. DOI: 10.1007/s10897-009-9240-1. View

12.

Tibben A, Timman R, Bannink E, Duivenvoorden H . Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners. Health Psychol. 1997; 16(1):20-35. DOI: 10.1037//0278-6133.16.1.20. View

13.

Gargiulo M, Lejeune S, Tanguy M, Lahlou-Laforet K, Faudet A, Cohen D . Long-term outcome of presymptomatic testing in Huntington disease. Eur J Hum Genet. 2008; 17(2):165-71. PMC: 2986057. DOI: 10.1038/ejhg.2008.146. View

14.

Rolim L, Leite A, Ledo S, Paneque M, Sequeiros J, Fleming M . Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I. Clin Genet. 2006; 69(4):297-305. DOI: 10.1111/j.1399-0004.2006.00606.x. View

15.

Almqvist E, Bloch M, Brinkman R, Craufurd D, Hayden M . A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet. 1999; 64(5):1293-304. PMC: 1377865. DOI: 10.1086/302374. View

16.

Bloch M, Fahy M, Fox S, Hayden M . Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet. 1989; 32(2):217-24. DOI: 10.1002/ajmg.1320320215. View

17.

Codori A, Slavney P, Young C, Miglioretti D, Brandt J . Predictors of psychological adjustment to genetic testing for Huntington's disease. Health Psychol. 1997; 16(1):36-50. DOI: 10.1037//0278-6133.16.1.36. View

18.

ZUNG W . A rating instrument for anxiety disorders. Psychosomatics. 1971; 12(6):371-9. DOI: 10.1016/S0033-3182(71)71479-0. View

19.

Decruyenaere M, Evers-Kiebooms G, Cloostermans T, Boogaerts A, Demyttenaere K, Dom R . Psychological distress in the 5-year period after predictive testing for Huntington's disease. Eur J Hum Genet. 2003; 11(1):30-8. DOI: 10.1038/sj.ejhg.5200913. View

20.

Gonzalez C, Gomes E, Kazachkova N, Bettencourt C, Raposo M, Kay T . Psychological well-being and family satisfaction levels five years after being confirmed as a carrier of the Machado-Joseph disease mutation. Genet Test Mol Biomarkers. 2012; 16(12):1363-8. PMC: 3501113. DOI: 10.1089/gtmb.2011.0370. View